{"id":"albiglutide-liquid-auto-injector","safety":{"commonSideEffects":[{"rate":"20–30","effect":"Nausea"},{"rate":"5–10","effect":"Vomiting"},{"rate":"15–20","effect":"Diarrhea"},{"rate":"5–10","effect":"Injection site reactions"},{"rate":"5–15","effect":"Hypoglycemia"}]},"_chembl":{"chemblId":"CHEMBL2107841","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Albiglutide binds to and activates GLP-1 receptors on pancreatic beta cells, enhancing glucose-dependent insulin secretion. It also slows gastric emptying and promotes satiety, contributing to improved glycemic control and modest weight loss. The liquid auto-injector formulation provides a convenient once-weekly subcutaneous delivery mechanism.","oneSentence":"Albiglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to stimulate insulin secretion and lower blood glucose in patients with type 2 diabetes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:00:28.840Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT02683746","phase":"PHASE3","title":"Safety and Efficacy Study of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-03-16","conditions":"Diabetes Mellitus, Type 2","enrollment":308},{"nctId":"NCT02750930","phase":"PHASE4","title":"Extension to Study 200952 to Evaluate the Long-term Safety, Tolerability and Pharmacodynamics of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus Subjects","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2016-10-07","conditions":"Diabetes Mellitus, Type 2","enrollment":8},{"nctId":"NCT02660736","phase":"PHASE1","title":"Bioequivalence Study of Two Albiglutide Drug Products in Healthy Adult Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-02","conditions":"Diabetes Mellitus, Type 2","enrollment":59}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Albiglutide liquid auto-injector","genericName":"Albiglutide liquid auto-injector","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Albiglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to stimulate insulin secretion and lower blood glucose in patients with type 2 diabetes. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}